Sei Investments Co. Boosts Holdings in Humana Inc (HUM)

Sei Investments Co. boosted its position in Humana Inc (NYSE:HUM) by 34.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 116,893 shares of the insurance provider’s stock after purchasing an additional 29,712 shares during the quarter. Sei Investments Co. owned approximately 0.08% of Humana worth $34,792,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. FDx Advisors Inc. boosted its holdings in Humana by 42.7% during the first quarter. FDx Advisors Inc. now owns 2,248 shares of the insurance provider’s stock worth $604,000 after buying an additional 673 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in Humana by 161.3% during the first quarter. Daiwa Securities Group Inc. now owns 11,478 shares of the insurance provider’s stock worth $3,086,000 after buying an additional 7,086 shares in the last quarter. Dean Capital Investments Management LLC boosted its holdings in Humana by 85.1% during the first quarter. Dean Capital Investments Management LLC now owns 4,171 shares of the insurance provider’s stock worth $1,121,000 after buying an additional 1,918 shares in the last quarter. Commerzbank Aktiengesellschaft FI boosted its holdings in Humana by 338.9% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 7,913 shares of the insurance provider’s stock worth $2,127,000 after buying an additional 6,110 shares in the last quarter. Finally, Alps Advisors Inc. boosted its holdings in Humana by 130.4% during the first quarter. Alps Advisors Inc. now owns 3,341 shares of the insurance provider’s stock worth $898,000 after buying an additional 1,891 shares in the last quarter. Institutional investors and hedge funds own 93.78% of the company’s stock.

Humana opened at $323.71 on Friday, according to Marketbeat. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. Humana Inc has a 52-week low of $231.90 and a 52-week high of $327.50. The firm has a market capitalization of $44.33 billion, a price-to-earnings ratio of 27.64, a P/E/G ratio of 1.60 and a beta of 0.93.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The business had revenue of $14.26 billion for the quarter, compared to analyst estimates of $14.16 billion. During the same period in the previous year, the business earned $3.49 EPS. research analysts forecast that Humana Inc will post 14.18 EPS for the current fiscal year.

In other news, SVP Cynthia H. Zipperle sold 1,000 shares of Humana stock in a transaction dated Wednesday, June 13th. The shares were sold at an average price of $306.01, for a total transaction of $306,010.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider William Kevin Fleming sold 15,637 shares of Humana stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $293.08, for a total transaction of $4,582,891.96. Following the sale, the insider now owns 15,650 shares in the company, valued at $4,586,702. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 104,976 shares of company stock worth $32,165,337. 0.60% of the stock is owned by company insiders.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday. Citigroup reaffirmed a “buy” rating and issued a $340.00 price objective (up previously from $280.00) on shares of Humana in a research note on Friday, June 1st. Argus raised their price objective on shares of Humana from $270.00 to $330.00 and gave the stock a “buy” rating in a research note on Monday, April 16th. Oppenheimer raised their price objective on shares of Humana from $305.00 to $311.00 and gave the stock an “outperform” rating in a research note on Thursday, May 3rd. Finally, Jefferies Financial Group raised their price objective on shares of Humana from $356.00 to $372.00 and gave the stock a “buy” rating in a research note on Thursday, August 2nd. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Humana presently has a consensus rating of “Buy” and a consensus target price of $318.17.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Featured Story: Are analyst ratings accurate?

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply